Tag
2 articles
German biotech Kupando has raised €10M to advance its innate immunity drug KUP101 into human clinical trials, targeting solid tumors and drug-resistant infections.
Zurich-based startup Rivia has raised €13 million to develop agentic AI systems that will streamline clinical trial operations and improve efficiency in drug development.